Highly potent anti-CD20-RLI immunocytokine targeting established human B lymphoma in SCID mouse

32Citations
Citations of this article
30Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Rituximab (RTX), a chimeric IgG1 monoclonal antibody directed against the CD20 antigen, has revolutionized the treatment of B-cell malignancies. Nevertheless, the relapsed/refractory rates are still high. One strategy to increase the clinical effectiveness of RTX is based on antibody-cytokine fusion protein (immunocytokine; ICK) vectorizing together at the tumor site the antibody effector activities and the cytokine co-signal required for the generation of cytotoxic cellular immunity. Such ICKs linking various antibody formats to interleukin (IL)-2 are currently being investigated in clinical trials and have shown promising results in cancer therapies. IL-15, a structurally-related cytokine, is now considered as having a better potential than IL-2 in antitumor immunotherapeutic strategies. We have previously engineered the fusion protein RLI, linking a soluble form of human IL-15Rα -sushi+ domain to human IL-15. Compared with IL-15, RLI displayed better biological activities in vitro and higher antitumor effects in vivo in murine and human cancer models. In this study, we investigated the advantages of fusing RLI to RTX. Anti-CD20-RLI kept its binding capacity to CD20, CD16 and IL-15 receptor and therefore fully retained both antibody effector functions (ADCC and CDC), and the cytokine potential of RLI. In a severe combined immunodeficiency (SCID) mouse model of disseminated residual lymphoma, anti-CD20-RLI was found to induce long-term survival of 90% of mice up to at least 120 days whereas RLI and RTX, alone or in combination, just delayed the disease onset (100% of death at 28, 40 and 51 days respectively). These findings suggest that such ICK could improve the clinical efficacy of RTX, particularly in patients with refractory B-cell lymphoma. © 2014 Landes Bioscience.

References Powered by Scopus

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program

2653Citations
N/AReaders
Get full text

Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

2470Citations
N/AReaders
Get full text

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial

1681Citations
N/AReaders
Get full text

Cited by Powered by Scopus

NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy

438Citations
N/AReaders
Get full text

Cytokines in cancer immunotherapy

365Citations
N/AReaders
Get full text

Cytokines in the Treatment of Cancer

364Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Vincent, M., Teppaz, G., Lajoie, L., Solé, V., Bessard, A., Maillasson, M., … Quéméner, A. (2014). Highly potent anti-CD20-RLI immunocytokine targeting established human B lymphoma in SCID mouse. MAbs, 6(4), 1026–1037. https://doi.org/10.4161/mabs.28699

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 10

59%

Researcher 6

35%

Professor / Associate Prof. 1

6%

Readers' Discipline

Tooltip

Biochemistry, Genetics and Molecular Bi... 6

38%

Immunology and Microbiology 4

25%

Engineering 3

19%

Agricultural and Biological Sciences 3

19%

Save time finding and organizing research with Mendeley

Sign up for free